Related Experiment Videos
[Immunotherapy in malignant melanoma]
L R Braathen1, R E Hunger, C U Brand
1Dermatologische Klinik, Universität Bern.
Abstract:
The malignant melanoma is because of its ability to form metastasis even at early stages of disease the deadliest of all skin tumors. Its incidence rises faster than that of any other human tumor. Today, treatment of melanoma is based on surgical removal, and depending on the stage, chemotherapy and/or biological response modifiers. The response and cure rates are, however, not satisfactory and there is, therefore, ongoing research for other approaches. The identification of melanoma antigenic peptides like Melan-A, gp100 and ras peptides has opened new possibilities in the treatment of malignant melanoma. The research on generating mainly T cell mediated immune responses against malignant melanoma using many different approaches like injection of dendritic cells pulsed with melanoma specific peptides, injection of in vitro with cytokines stimulated T cells, immunization with peptides in the presence of different adjuvants, immunization with genetically modified melanoma cells etc. has produced many encouraging results. However, the future of tumor-vaccine development still lies in generation of more potent vaccination protocols.
Insights
Malignant melanoma, a deadly skin cancer, is increasingly researched for new treatments. Immunotherapy using melanoma-specific peptides shows promise, but more potent vaccination strategies are needed for better outcomes.
Area of Science:
- Oncology
- Immunology
- Dermatology
Context:
- Malignant melanoma is the deadliest skin tumor, with rising incidence and unsatisfactory treatment outcomes.
- Current treatments include surgery, chemotherapy, and biological response modifiers, necessitating novel therapeutic strategies.
Purpose:
- To explore the potential of immunotherapy targeting melanoma-specific antigenic peptides for treating malignant melanoma.
- To review current research on generating T cell-mediated immune responses against melanoma.
Summary:
- Identification of melanoma antigenic peptides (e.g., Melan-A, gp100) has opened avenues for targeted immunotherapy.
- Various approaches, including dendritic cell vaccination and peptide immunization, have shown encouraging results in eliciting anti-melanoma immune responses.
- Future advancements depend on developing more potent tumor-vaccine protocols.
Impact:
- Advances in melanoma immunotherapy could lead to improved treatment efficacy and patient survival rates.
- This research highlights the importance of peptide-based vaccines in the development of novel cancer therapies.